Rheumatology Department

Rheumatology Department

1.Member institution of International Network of Scleroderma Clinical Care and Research (InSCAR)

2.TCM key specialty institution of Hebei Province
3.Clinical and Research Base for Rheumatism and Immune Diseases of Chinese Medical Association.

1. Introduction

Rheumatology and Autoimmune Diseases Department of Hebei Yiling Hospital, is a member institution of International Network of Scleroderma Clinical and Research (InSCAR), key TCM specialty department of Hebei Province, the Clinical and Research Base of Rheumatoid and Autoimmune Diseases of Chinese Medical Association, and the largest and earliest established scleroderma treatment center in China. With over twenty years of development, the department has become a significant characteristic specialty both at home and abroad, and developed 34 TCM preparations which have been approved by Hebei Food and Drugs Administration, and mainly treated scleroderma, multiple myositis, ankylosing spondylitis, rheumatoid diseases, Sjögren's syndrome, Behcet's syndrome, etc. Particularly, the department is in a leading position for treating scleroderma, and has the largest number of inpatients with scleroderma throughout the world with over 12000 cases of scleroderma.

On the basis of fully tapping TCM traditional theories, the department established for scleroderma and its complications a scleroderma research lab which has innovated many treatment theories and methods, such as diagnosis and treatment from the perspective of collateral pathology, softening scleroderma with TCM medication in three phases, treating scleroderma pulmonary fibrosis with three differentiations and three combinations according to different phases, treating systematic scleroderma with the combination of TCM and thoracic duct drainage, and also conducted clinical researches on treating systematic scleroderma esophageal lesion with Shenzhe Zhuyun mixture, treating scleroderma pulmonary fibrosis with combination of Shenmai Kaifei powder and pirfenidone and treating scleroderma with mesenchymal stem cell, etc.

While conducting substantial clinical practice, the department has also attached the same importance to scientific research, carried out cooperation on scleroderma with medical institutions like UT Health, Fudan University, Shanghai Huashan Hospital, taken on one international cooperation project (NIH-UO1) of the National Institution of Health of the United States, one special international cooperation project of the Ministry of Science and Technology, one project of the National Natural Science Foundation of China and four project of provincial science and research, published over 20 professional papers on scleroderma, and related research results have been shared many times at professional conferences both at home and abroad. The clinical efficacy and research competence of the department has been highly appreciated by the general patients and professionals both at home and abroad.